Dr. James Yao on Everolimus in Advanced Pancreatic Neuroendocrine Tumors

0 Views
administrator
administrator
07/09/23

James C. Yao, MD, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, describes the administration of the mTOR inhibitor everolimus (Afinitor) for patients with pancreatic neuroendocrine tumors (NET).

For more GI cancer resources, visit http://www.onclive.com/special....ty/gastrointestinal-

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next